AI-generated analysis. Always verify with the original filing.
CollPlant Biotechnologies reported 2025 financial results with GAAP revenues of $2.4 million, up from $515,000 in 2024 due to a $2 million AbbVie milestone payment, and a reduced GAAP net loss of $11.5 million or $0.94 per share versus $16.6 million or $1.45 per share prior year. The company highlighted pipeline progress, including rhCollagen bioprinting launches, breast implant preclinical data, and new patents, alongside cost reductions and a $3.1 million financing.
Event Type
Disclosure
Voluntary
Variant
6-K
Current Report on Form 6-K
| Metric | Value | Basis |
|---|---|---|
| Revenues | $2.40 | GAAP |
| Cost of Revenues | $0.84 | GAAP |
| Gross Profit | $1.50 | GAAP |
| Operating Expenses | $13.00 | GAAP |
| Operating Expenses | $12.10 | Non-GAAP |
| Net Loss | $11.50 | GAAP |
| Basic Loss per Share | $0.94 | GAAP |
| Net Loss | $10.20 | Non-GAAP |
| Basic Loss per Share | $0.83 | Non-GAAP |